EBMT Annual report 2023



ScienceEducationPatient Care & Advocacy

Our SocietyOur Mission, Vision & ValuesEBMT Membership 2023Organisational Structure 2023Financial Highlights 2023EBMT Partners

## **Breadcrumb**

1. Home

# **Entity Print**



Zinaida Perić TCWP Chair Croatia

## **Major achievements**

During 2023 the TCWP finalised several important projects including the **new guidelines** on prevention and management of GVHD as well as joint ERS/EBMT Task force guidelines on pulmonary GVHD which are both in the process of publications.

Several other important **studies** were also finalised in the form of publications, including the first real-life experience with cytopenias and organ complications after CAR-T therapies as well as the first AI study conducted in the TCWP on the mortality and NRM after allogeneic HSCT.

Furthermore, the TCWP followed the same successful format of the previous year and conducted a successful **educational meeting** in September in Copenhagen in a format of patient case discussion and sharing practical skills. Patient advocates, nurses and physicians all participated, significantly improving the audience engagement in the activities and resulting in a very positive feedback.

Finally, significant work was also done in the **harmonisation of definitions** for the new EBMT Registry to improve the quality and speed of TCWP studies in the future.

## **Principal research studies**

Daratumumab for PRCA after alloSCT

Study type

**Retrospective Studies** 

Diseases

Complications: non-infectious

Group

**Transplant Complications Working Party (TCWP)** 

Type of treatment

\_

Principal investigator

Nico Gagelmann

Immune Checkpoint Inhibitors for solid tumors after allogeneic stem cell

<u>transplantation</u>

Study type

**Retrospective Studies** 

<u>Diseases</u>

All diseases

Group

<u>Transplant Complications Working Party (TCWP)</u>

Type of treatment

Allogeneic

Principal investigator

Jan Brijs
Outcomes of Allogeneic Hematopoietic Cell Transplantation from ≤8/10-HLA
matched unrelated donor
Study type
Retrospective Studies
<u>Diseases</u>
All diseases
Group
Transplant Complications Working Party (TCWP)
Type of treatment
<u>Allogeneic</u>
Principal investigator
<u>Ivan Moiseev</u>
Outcomes and risk factors for survival of lung transplantation after allogeneic HSCT
Study type
Retrospective Studies
<u>Diseases</u>
<u>Group</u>
Transplant Complications Working Party (TCWP)
Type of treatment

Type of treatment

<u>Allogeneic</u>

**Principal investigator** 

Juan Montoro Gomez; Saskia Bos

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Study type

**Retrospective Studies** 

<u>Diseases</u>

All diseases

Group

Transplant Complications Working Party (TCWP)

Type of treatment

Allogeneic

**Principal investigator** 

**Olaf Penack** 

<u>Evaluating the Impact of ABO Compatibility on Allogeneic Stem Cell Transplantation</u>
Outcomes

Study type

**Retrospective Studies** 

Diseases

All diseases

Group

Transplant Complications Working Party (TCWP)

Type of treatment

Allogeneic

**Principal investigator** 

Mustafa Güven

## **Key publications**

2023

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Infectious Diseases Working Party (IDWP)

Transplant Complications Working Party (TCWP)

1st listed author

Olaf Penack

Journal

J Immunother Cancer.

2023

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working

party

Group

**Transplant Complications Working Party (TCWP)** 

Lymphoma Working Party (LWP)

1st listed author

<u>Olaf Penack</u>

Journal

Front Immunol.

<u>2023</u>

ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party

Group

Transplant Complications Working Party (TCWP)

1st listed author

**Olaf Penack** 

Journal

Front Immunol.

2023

The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

Group

Transplant Complications Working Party (TCWP)

1st listed author

Lars Klingen Gjærde

**Journal** 

Bone Marrow Transplant.

2023

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

<u>Group</u>

Transplant Complications Working Party (TCWP)

1st listed author

<u>A Mussetti</u>

Journal

Bone Marrow Transplant.

2023

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study

Group

Transplant Complications Working Party (TCWP)

1st listed author

Tapani Ruutu

**Journal** 

Bone Marrow Transplant.

2023

Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications

Working Party of the EBMT

Group

**Transplant Complications Working Party (TCWP)** 

1st listed author

Lars Klingen Gjærde

Journal


Bone Marrow Transplant.




#### 2021 2022 2023

Oral presentations 2 6 1
Poster presentations 2 5 9
Educational events 1 1 1

## **Major educational events**



### **Event**



## **Event**

# TCWP Educational Meeting 2023 on How to survive stem cell transplantation and CAR T-cell therapy - guide for physicians and nurses

Sep 14, 2023 - Sep 16, 2023 / Copenhagen, Denmark

<u>Discover more</u>

VISIT THE TCWP WEBPAGE